Protective Effects of Influenza B Neuraminidase Antibodies Against Symptomatic Influenza Virus Infection
The Journal of Infectious Diseases · 15.10.2026 · 234 (4) · 573-582
DOI: 10.1093/infdis/jiag351 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 10.07.2026. Verfasst von Skyler Rogers und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Neuraminidase, Antibodies, Viral, Influenza B virus, Influenza Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, NIH HHS, HHS.
Abstract (Originalsprache)
Background
Influenza vaccines are designed to induce hemagglutinin-inhibiting (HAI) antibodies rather than neuraminidase-inhibiting (NAI) antibodies; therefore, NAI antibodies’ protective effects need further investigation. Neuraminidase-inhibiting antibodies’ protective effects, independent of HAI antibodies, have been demonstrated for influenza A viruses, but not influenza B viruses (IBVs).
Methods
Employing H6NB reassortant virus targets, we evaluated NAI antibodies’ protective effects against IBV in sera from a prospective influenza vaccine effectiveness study among healthcare personnel (HCP) in Israel. Antibody titers against B/Brisbane/60/2008 and B/Phuket/3073/2013 were quantified by HAI and NAI assays. Matched NAI and HAI antibody titers from baseline and postvaccination sera were analyzed for the 2017–2018 influenza season.
Results
Laboratory-confirmed IBV infection was recorded in 64/262 HCP and influenza vaccination in 187/262 HCP. Vaccination did not consistently elicit rising NAI titers against vaccine strain B/Brisbane, with a geometric mean fold rise of 1.1 (95% CI: .9–1.3). However, comparing baseline NAI titers, geometric mean titer ratios were 1.50 (95% CI: 1.0–2.1) times higher against B/Brisbane and 2.5 (95% CI: 1.7–3.6) times higher against circulating B/Phuket in vaccinated versus unvaccinated HCP. Each 2-fold rise in NAI antibody titers reduced the hazard of symptomatic infection by 42% (95% CI: 36%–48%) against B/Phuket and 23% (95% CI: 13%–33%) against B/Brisbane, adjusting for HAI titers.
Conclusions
Neuraminidase-inhibiting antibodies were a strong correlate of protection against symptomatic IBV infection, with protective effects independent of those from HAI antibodies. These findings suggest that the use and standardization of neuraminidase content in influenza vaccines could provide broader protection against influenza.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA.
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel.
- School of Public Health, Faculty of Social Welfare and Health Studies, University of Haifa, Haifa, Israel.
- Beilinson Campus, Rabin Medical Center, Petah Tikva, Israel.
- Saban Children's Hospital, Soroka University Medical Center, Be'er Sheva, Israel.
ORCID-Profile: Skyler Rogers, Yangyupei Yang, Avital Hirsch, Florian Krammer, Arnold S Monto, Emily T Martin
Förderung
- National Institute of Allergy and Infectious Diseases
- NIH HHS
- HHS
- National Institutes of Health
- Department of Health and Human Services
Zitieren
APA
Rogers, S., Sumner, K. M., Yang, Y., Johnson, E., Balicer, R., Peretz, A., Greenberg, D., Hirsch, A., Katz, M. A., Krammer, F., Monto, A. S., & Martin, E. T. (2026). Protective Effects of Influenza B Neuraminidase Antibodies Against Symptomatic Influenza Virus Infection. The Journal of Infectious Diseases, 234(4), 573-582. https://doi.org/10.1093/infdis/jiag351
Vancouver
Rogers S, Sumner KM, Yang Y, Johnson E, Balicer R, Peretz A, et al. Protective Effects of Influenza B Neuraminidase Antibodies Against Symptomatic Influenza Virus Infection. The Journal of Infectious Diseases. 2026;234(4):573-582. doi:10.1093/infdis/jiag351
BibTeX
@article{Rogers2026,
author = {Rogers, Skyler and Sumner, Kelsey M and Yang, Yangyupei and Johnson, Emileigh and Balicer, Ran and Peretz, Alon and Greenberg, David and Hirsch, Avital and Katz, Mark A and Krammer, Florian and Monto, Arnold S and Martin, Emily T},
title = {Protective Effects of Influenza B Neuraminidase Antibodies Against Symptomatic Influenza Virus Infection},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {234},
number = {4},
pages = {573--582},
doi = {10.1093/infdis/jiag351}
}
EUVIMED